Search

Your search keyword '"Mercuri, Michele"' showing total 530 results
Start Over Author "Mercuri, Michele"
530 results on '"Mercuri, Michele"'

4. Developing a large-scale dataset of flood fatalities for territories in the Euro-Mediterranean region, FFEM-DB

Author

Papagiannaki, Katerina, Petrucci, Olga, Diakakis, Michalis, Kotroni, Vassiliki, Aceto, Luigi, Bianchi, Cinzia, Brázdil, Rudolf, Gelabert, Miquel Grimalt, Inbar, Moshe, Kahraman, Abdullah, Kılıç, Özgenur, Krahn, Astrid, Kreibich, Heidi, Llasat, Maria Carmen, Llasat-Botija, Montserrat, Macdonald, Neil, de Brito, Mariana Madruga, Mercuri, Michele, Pereira, Susana, Řehoř, Jan, Geli, Joan Rossello, Salvati, Paola, Vinet, Freddy, and Zêzere, José Luis

Published
2022
Full Text
View/download PDF

5. Forest Fires: Silvicultural Prevention and Mathematical Models for Predicting Fire Propagation in Southern Italy.

Author

Marziliano, Pasquale A., Lombardi, Fabio, Cataldo, Maria F., Mercuri, Michele, Papandrea, Salvatore F., Manti, Leonardo M., Bagnato, Silvio, Alì, Giuseppe, Fusaro, Pierpaolo, Pantano, Pietro S., and Scuro, Carmelo

Subjects
FOREST fire prevention & control, FOREST fire management, FOREST fires, FOREST density, MOUNTAIN forests
Abstract

In the Mediterranean basin, coniferous reforestation mainly comprises forest stands highly susceptible to fires. When silvicultural treatments have not been performed for decades after plantation, these stands often exhibit high vertical and horizontal tree density, along with a significant occurrence of lying and standing deadwood, thereby increasing the fuel load. On average, these pine forests are characterized by high values of above-ground biomass, ranging from 175 to 254 Mg ha−1 for the younger and the older ones, respectively. The theoretical heat energy produced per surface unit, in the case of the total combustion of the above-ground biomass, is also high, varying from 300 to 450 MJ ha−1 depending on the stage of stand development. In this study, we demonstrated the importance of silvicultural interventions in reducing the pyrological potential in pine reforested stands located in southern Italy, also giving attention to the water savings needed during extinction phases. In detail, we applied a preliminary mathematical reaction-diffusion model aimed at predicting the development of forest fires. The model was applied using data obtained through the estimation of the pyrological potential in terms of heat energy produced per surface unit (1 hectare) and the variation in the critical surface intensity. We verified that, when silvicultural interventions are applied, they induce a reduction of heat energy ranging between 17 and 21%, while the extinguishing water saved ranges between 600 and 1000 Mg ha−1. Moreover, when the silvicultural interventions are implemented, the probability of the transition from surface fire to crown fire can be reduced by up to 31%. The most effective results on fire risk mitigation are mainly obtained when thinning aimed at reducing canopy and tree density is carried out in the younger phases of the reforested pine stands. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.

Author

Bergmark, Brian A., Park, Jeong-Gun, Hamershock, Rose A., Melloni, Giorgio E. M., De Caterina, Raffaele, Antman, Elliott M., Ruff, Christian T., Rutman, Howard, Mercuri, Michele F., Lanz, Hans-Joachim, Braunwald, Eugene, and Giugliano, Robert P.

Abstract

BACKGROUND: Cardiovascular trials often use a composite end point and a time-to-first event model. We sought to compare edoxaban versus warfarin using the win ratio, which offers data complementary to time-to-first event analysis, emphasizing the most severe clinical events. METHODS: ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a double-blind, randomized trial in which patients with atrial fibrillation were assigned 1:1:1 to a higher dose edoxaban regimen (60/30 mg daily), a lower dose edoxaban regimen (30/15 mg daily), or warfarin. In an exploratory analysis, we analyzed the trial outcomes using an unmatched win ratio approach. The win ratio for each edoxaban regimen was the total number of edoxaban wins divided by the number of warfarin wins for the following ranked clinical outcomes: 1: death; 2: hemorrhagic stroke; 3: ischemic stroke/systemic embolic event/epidural or subdural bleeding; 4: noncerebral International Society on Thrombosis and Haemostasis major bleeding; and 5: cardiovascular hospitalization. RESULTS: 21 105 patients were randomized to higher dose edoxaban regimen (N=7035), lower dose edoxaban regimen (N=7034), or warfarin (N=7046), yielding >49 million pairs for each treatment comparison. The median age was 72 years, 38% were women, and 59% had prior vitamin K antagonist use. The win ratio was 1.11 (95% CI, 1.05-1.18) for higher dose edoxaban regimen versus warfarin and 1.11 (95% CI, 1.05-1.18) for lower dose edoxaban regimen versus warfarin. The favorable impacts of edoxaban on death (34% of wins) and cardiovascular hospitalization (41% of wins) were the major contributors to the win ratio. Results consistently favored edoxaban in subgroups based on creatine clearance and dose reduction at baseline, with heightened benefit among those without prior vitamin K antagonist use. CONCLUSIONS: In a win ratio analysis of the ENGAGE AF-TIMI 48 trial, both dose regimens of edoxaban were superior to warfarin for the net clinical outcome incorporating ischemic and bleeding events. As the win ratio emphasizes the most severe clinical events, this analysis supports the superiority of edoxaban over warfarin in patients with atrial fibrillation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Author

Garcia-Pavia, Pablo, primary, aus dem Siepen, Fabian, additional, Donal, Erwan, additional, Lairez, Olivier, additional, van der Meer, Peter, additional, Kristen, Arnt V., additional, Mercuri, Michele F., additional, Michalon, Aubin, additional, Frost, Robert J.A., additional, Grimm, Jan, additional, Nitsch, Roger M., additional, Hock, Christoph, additional, Kahr, Peter C., additional, and Damy, Thibaud, additional

Published
2023
Full Text
View/download PDF

10. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Author

Garcia-Pavia, Pablo, Aus dem Siepen, Fabian, Donal, Erwan, Lairez, Olivier, van der Meer, Peter, Kristen, Arnt V, Mercuri, Michele F, Michalon, Aubin; https://orcid.org/0000-0002-5246-4881, Frost, Robert J A, Grimm, Jan, Nitsch, Roger M, Hock, Christoph, Kahr, Peter C, Damy, Thibaud, Garcia-Pavia, Pablo, Aus dem Siepen, Fabian, Donal, Erwan, Lairez, Olivier, van der Meer, Peter, Kristen, Arnt V, Mercuri, Michele F, Michalon, Aubin; https://orcid.org/0000-0002-5246-4881, Frost, Robert J A, Grimm, Jan, Nitsch, Roger M, Hock, Christoph, Kahr, Peter C, and Damy, Thibaud

Abstract

BACKGROUND Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the amelioration of cardiac dysfunction. NI006 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells. METHODS In this phase 1, double-blind trial, we randomly assigned (in a 2:1 ratio) 40 patients with wild-type or variant ATTR cardiomyopathy and chronic heart failure to receive intravenous infusions of either NI006 or placebo every 4 weeks for 4 months. Patients were sequentially enrolled in six cohorts that received ascending doses (ranging from 0.3 to 60 mg per kilogram of body weight). After four infusions, patients were enrolled in an open-label extension phase in which they received eight infusions of NI006 with stepwise increases in the dose. The safety and pharmacokinetic profiles of NI006 were assessed, and cardiac imaging studies were performed. RESULTS The use of NI006 was associated with no apparent drug-related serious adverse events. The pharmacokinetic profile of NI006 was consistent with that of an IgG antibody, and no antidrug antibodies were detected. At doses of at least 10 mg per kilogram, cardiac tracer uptake on scintigraphy and extracellular volume on cardiac magnetic resonance imaging, both of which are imaging-based surrogate markers of cardiac amyloid load, appeared to be reduced over a period of 12 months. The median N-terminal pro-B-type natriuretic peptide and troponin T levels also seemed to be reduced. CONCLUSIONS In this phase 1 trial of the recombinant human antibody NI006 for the treatment of patients with ATTR cardiomyopathy and heart failure, the use of NI006 was associated with no apparent drug-related serious adverse events. (Funded by Neurimmune; NI006-101 ClinicalTrials.gov number, NCT04360434.).

Published
2023

12. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Author

Goette, Andreas, Merino, Jose L, Ezekowitz, Michael D, Zamoryakhin, Dmitry, Melino, Michael, Jin, James, Mercuri, Michele F, Grosso, Michael A, Fernandez, Victor, Al-Saady, Naab, Pelekh, Natalya, Merkely, Bela, Zenin, Sergey, Kushnir, Mykola, Spinar, Jindrich, Batushkin, Valeriy, de Groot, Joris R, and Lip, Gregory Y H

Published
2016
Full Text
View/download PDF

22. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Author

Raskob, Gary E., van Es, Nick, Verhamme, Peter, Carrier, Marc, Di Nisio, Marcello, Garcia, David, Grosso, Michael A., Kakkar, Ajay K., Kovacs, Michael J., Mercuri, Michele F., Meyer, Guy, Segers, Annelise, Shi, Minggao, Wang, Tzu-Fei, Yeo, Erik, Zhang, George, Zwicker, Jeffrey I., Weitz, Jeffrey I., and Büller, Harry R.

Published
2018
Full Text
View/download PDF

26. Developing a large-scale, fine-resolution dataset of flood fatalities for territories in the Euro-Mediterranean region and beyond

Author

Papagiannaki, Katerina, Petrucci, Olga, Diakakis, Michalis, Kotroni, Vassiliki, Aceto, Luigi, Bianchi, Cinzia, Brázdil, Rudolf, Grimalt Gelabert, Miquel, Inbar, Moshe, Kahraman, Abdullah, Kılıç, Özgenur, Krahn, Astrid, Kreibich, Heidi, Llasat, Maria Carmen, Llasat Botija, Montserrat, Macdonald, Neil, Madruga de Brito, Mariana, Mercuri, Michele, Pereira, SUsana, Řehoř, Jan, Rossello Geli, Joan, Salvati, Salvati, Vinet, Freddy, and Luis Zêzere, José

Subjects
Control d'inundacions, Information resources management, Gestió de la informació, Flood control
Abstract

This data paper describes the multinational Database of Flood Fatalities from the Euro-Mediterranean region FFEM-DB that hosts data of 2,875 food fatalities from 12 territories (nine of which represent entire countries) in Europe and the broader Mediterranean region from 1980 to 2020. The FFEM-DB database provides data on fatalities' profles, location, and contributing circumstances, allowing researchers and food risk managers to explore demographic, behavioral, and situational factors, as well as environmental features of food-related mortality. The standardized data collection and classifcation methodology enable comparison between regions beyond administrative boundaries. The FFEM-DB is expandable, regularly updated, publicly available, and with anonymized data. The key advantages of the FFEM-DB compared to existing datasets containing food fatalities are its high level of detail, data accuracy, record completeness, and the large sample size from an extended area.

Published
2022

29. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)

Author

Link, Mark S., Giugliano, Robert P., Ruff, Christian T., Scirica, Benjamin M., Huikuri, Heikke, Oto, Ali, Crompton, Andrea E., Murphy, Sabina A., Lanz, Hans, Mercuri, Michele F., Antman, Elliott M., and Braunwald, Eugene

Published
2017
Full Text
View/download PDF

30. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

Author

Rost, Natalia S., Giugliano, Robert P., Ruff, Christian T., Murphy, Sabina A., Crompton, Andrea E., Norden, Andrew D., Silverman, Scott, Singhal, Aneesh B., Nicolau, José C., SomaRaju, Bhupathi, Mercuri, Michele F., Antman, Elliott M., and Braunwald, Eugene

Published
2016
Full Text
View/download PDF

32. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial

Author

Eisen, Alon, Giugliano, Robert P., Ruff, Christian T., Nordio, Francesco, Gogia, Harinder S., Awasty, Vivek R., Henderson, David A., Mercuri, Michele F., Rutman, Howard, Antman, Elliott M., and Braunwald, Eugene

Published
2016
Full Text
View/download PDF

34. The Energy of crisis. Towards Renewable Energy Community

Author

Cilio, Debora, primary, Barone, Giuseppe, additional, Vizza, Pasquale, additional, Polizzi, Gaetano, additional, Mendicino, Stefano, additional, Mercuri, Michele, additional, Mendicino, Luca, additional, Vizza, Maurizio, additional, and Brusco, Giovanni, additional

Published
2021
Full Text
View/download PDF

37. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study

Author

de Groot, Joris R., primary, Ruff, Christian T., additional, Murphy, Sabina A., additional, Hamershock, Rose A., additional, Vehmeijer, Jim T., additional, Oude Ophuis, Anton J.M., additional, Grip, Laura, additional, Lanz, Hans, additional, Mercuri, Michele F., additional, Antman, Elliott M., additional, and Giugliano, Robert P., additional

Published
2021
Full Text
View/download PDF

39. Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Author

Giugliano, Robert P., Ruff, Christian T., Rost, Natalia S., Silverman, Scott, Wiviott, Stephen D., Lowe, Cheryl, Deenadayalu, Naveen, Murphy, Sabina A., Grip, Laura T., Betcher, Joshua M., Duggal, Anil, Dave, Jay, Shi, Minggao, Mercuri, Michele, Antman, Elliott M., and Braunwald, Eugene

Published
2014
Full Text
View/download PDF

42. Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Author

Giugliano, Robert P., Ruff, Christian T., Braunwald, Eugene, Murphy, Sabina A., Wiviott, Stephen D., Halperin, Jonathan L., Waldo, Albert L., Ezekowitz, Michael D., Weitz, Jeffrey I., Špinar, Jindřich, Ruzyllo, Witold, Ruda, Mikhail, Koretsune, Yukihiro, Betcher, Joshua, Shi, Minggao, Grip, Laura T., Patel, Shirali P., Patel, Indravadan, Hanyok, James J., Mercuri, Michele, and Antman, Elliott M.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results